Regeneron Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 12.1% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) now have 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $1,066.00 and $680.00 with the average target price sitting at $920.09. Now with the previous closing price of $820.90 and the analysts are correct then we can expect a percentage increase in value of 12.1%. It’s also worth noting that there is a 50 day moving average of $812.88 while the 200 day moving average is $785.65. The total market capitalization for the company now stands at 91.05B. The stock price for the company is currently $835.75 USD

The potential market cap would be $102,054,398,912 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 23.86, revenue per share of $122.63 and a 9.21% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search